Full-Time

Scientist/Sr. Scientist

In Vitro Pharmacology

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

Compensation Overview

$108.6k - $157.3kAnnually

+ Annual Bonus (20% of base salary) + Equity-based long term incentive program

Mid, Senior

San Diego, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis

You match the following Neurocrine Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS/BA degree in scientific field and 5+ years of in vitro pharmacology experience; Preferred experience includes: SPR and BLI for characterizing protein-protein interactions and binding kinetics, related assay development and troubleshooting OR
  • MS/MA degree in scientific field and 3+ years of similar experience noted above OR
  • PhD in biology or related field preferred and some experience with antibody drug discovery, antibody characterizations, assay development and optimization and related troubleshooting, experience with SPR and BLI is required. Preferred experience includes: SPR and BLI for characterizing antibody-protein interactions with strong assay development and troubleshooting skills
  • Recognizes fundamental anomalies in data points and identifies issues in experiments / processes
  • Begins to understand how to think outside of the technical process and consider the impact decisions will have on the broader scientific goals
  • Strong knowledge of one scientific discipline
  • Good knowledge of scientific principles, methods and techniques
  • Good knowledge and demonstrated ability working with a variety of laboratory equipment/tools
  • Ability to work as part of a team
  • Strong computer skills
  • Good communications, problem-solving, analytical thinking skills
  • Detail oriented
  • Ability to meet deadlines
  • Good project management skills
  • Demonstrated experience with measuring antibody binding kinetics, pH dependent, competition binding, dual engagement binding studies using Biacore SPR methods
  • Experience with obtaining epitope binning and binding/competition binding studies using Octet BLI methods
  • Ability to QC and troubleshoot experiments
  • Collaborative and highly motivated
Responsibilities
  • Design, execute, and analyze SPR and BLI experiments to determine antibody affinity (KD), kinetics, pH dependent binding, competition experiments, dual-target engagement, epitope binning against various antigens, including recombinant proteins, Nanodisc, VLP. Experience with cells a plus
  • Independently develop, optimize and troubleshoot protocols to evaluate monospecific and bispecific antibodies, scFv, Fabs, peptides and small molecules
  • Apply extensive QC parameters to data to identify and troubleshoot issues
  • Extensive knowledge of Biacore Insight and Octet Analysis software for data analysis
  • Regular maintenance of SPR and BLI instrumentation
  • Prepare high-quality data reports and presentations for project meetings
  • Collaborate with scientists in a highly matrixed environment across multiple therapeutic areas and function teams
  • Stay current with the latest advancements in SPR, BLI, and antibody, peptide and small molecule characterization techniques
  • Must be highly organized with strong attention to details, and an eye on critical decision-making data generation
Desired Qualifications
  • Experience measuring binding kinetics on cells is a plus
  • PhD in biology or related field preferred
  • Preferred experience includes: SPR and BLI for characterizing antibody-protein interactions with strong assay development and troubleshooting skills
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Crenessity's launch in the US taps into the growing rare disease treatment market.
  • Strategic collaborations with Takeda and Nxera enhance Neurocrine's drug development pipeline.
  • FDA initiatives expedite approval processes, benefiting Neurocrine's first-in-class therapies.

What critics are saying

  • Increased competition in the muscarinic agonist market from companies like Karuna Therapeutics.
  • Global expansion of Crenessity faces regulatory and market access challenges.
  • Reliance on PANTHERx Rare for Crenessity distribution poses supply chain risks.

What makes Neurocrine Biosciences unique

  • Neurocrine's Crenessity is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • The company has exclusive worldwide rights to develop osavampator, except in Japan.
  • Neurocrine's muscarinic agonist portfolio targets schizophrenia and dementia with subtype-selective therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

PR Newswire
Jan 27th, 2025
Neurocrine Biosciences Announces Amendment To Strategic Collaboration With Takeda To Develop And Commercialize Osavampator (Formerly Nbi-1065845/Tak-653)

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator- Takeda Reacquires Rights to Osavampator in JapanSAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments."This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible," said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.""With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator," said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda

PR Newswire
Jan 21st, 2025
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today In The Journal Of Clinical Endocrinology Metabolism

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, patients and caregivers in advancing the understanding and management of various endocrinology conditions, such as CAH."Our understanding of the genetics, pathophysiology, and complications of CAH has exploded over the last 20 years," said Dr. Richard Auchus, M.D., Ph.D., Principal Investigator, Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan

ForexTV
Jan 14th, 2025
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Nxera for the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

PR Newswire
Jan 6th, 2025
Neurocrine Biosciences To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com

PR Newswire
Dec 23rd, 2024
Neurocrine Biosciences, Inc. Selects Pantherx®Rare Specialty Pharmacy For Distribution Of Crenessity™ (Crinecerfont)

PITTSBURGH, Dec. 23, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Neurocrine Biosciences, Inc. for the distribution of CRENESSITY™ (crinecerfont), an oral selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist indicated to improve androgen control and enable a reduced glucocorticoid dose in patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH). CRENESSITY is the first non-steroidal treatment approved for classic CAH and a first-in-class therapy that provides a novel approach to treatment for this rare disorder.CAH is a rare, autosomal recessive genetic disorder that results from deficiency of one of the enzymes needed for adrenal hormone production. The most common cause of CAH is 21-hydroxylase (21-OHD) deficiency, which accounts for approximately 95% of cases.2 21-OHD deficiency prevents the body from producing cortisol, which is essential to respond to stress and illness. In about 75% of cases, aldosterone production is also affected, which impairs the body's ability to regulate salt and water levels, and thereby blood pressure.2,3 In response to low levels of cortisol and aldosterone, the hypothalamus-pituitary-adrenal (HPA) axis is activated, leading to overproduction of androgens.2 Excess androgen production can cause a variety of symptoms, including anxiety, acne, hirsutism, atypical genital development in affected females, fertility issues, early-onset puberty, and rapid growth followed by premature completion resulting in short stature.3 These symptoms can significantly impact both the physical and mental health of those affected with CAH."We are proud to partner with Neurocrine Biosciences for the distribution of CRENESSITY

Investing.com
Dec 21st, 2024
Neurocrine launches CRENESSITY for adrenal hyperplasia in US

Neurocrine launches CRENESSITY for adrenal hyperplasia in US.

Investing.com
Dec 20th, 2024
BofA raises Neurocrine Bio target to $182 on drug launch

In other recent news, Neurocrine Biosciences has launched CRENESSITY, a new treatment for congenital adrenal hyperplasia (CAH), in the United States.

PR Newswire
Dec 20th, 2024
Neurocrine Biosciences Announces Commercial Availability Of Crenessity™ (Crinecerfont) For Children And Adults With Classic Congenital Adrenal Hyperplasia

CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S.CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacyNeurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providersSAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is a first-in-class therapy for classic CAH that directly reduces adrenocorticotropic hormone and downstream adrenal androgen production. It is the first and only classic CAH treatment that allows people to take lower doses of glucocorticoids while maintaining or improving their androgen levels."Individuals with CAH and their families have faced ongoing challenges with managing the condition with high-dose steroids alone for the past 70 years," said Kyle W

Investing.com
Dec 20th, 2024
Neurocrine launches CRENESSITY for adrenal hyperplasia in US

Neurocrine launches CRENESSITY for adrenal hyperplasia in US.

The Pharma Letter
Dec 20th, 2024
Neurocrine Biosciences launches Crenessity in USA

San Diego, USA-based Neurocrine Biosciences (Nasdaq: NBIX) today announced the launch of its Crenessity (crinecerfont) in the USA.

GeneOnline
Dec 17th, 2024
Neurocrine's First New CAH Treatment in 70 Years Gets FDA Approval

Neurocrine Biosciences has introduced a new FDA-approved therapy for classic congenital adrenal hyperplasia (CAH), a rare endocrine disorder traditionally treated with steroids that cause various side effects.

PR Newswire
Dec 14th, 2024
Neurocrine Biosciences Announces Fda Approval Of Crenessity™ (Crinecerfont), A First-In-Class Treatment For Children And Adults With Classic Congenital Adrenal Hyperplasia

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach. FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH. CRENESSITY is expected to be commercially available in approximately one week